{"title":"Gut Microbes: A Plausible Association Between Inflammaging and Metabolic Disorders","authors":"Mohammad Sajid, S. Negi","doi":"10.37290/ijpp2641-7197.15:34-44","DOIUrl":null,"url":null,"abstract":"Aging is associated with deterioration of cellular homeostasis and increased risk for several age-related metabolic disorders like obesity, diabetes mellitus, and cardiovascular diseases. Chronic and low-grade inflammation is linked with metabolic syndromes especially during aging (inflammaging). This inflammaging may enhance the risk for late-onset diseases. Gut microbes show a significant role in the regulation and pathogenesis of various metabolic disorders. Gut mucosal lining is a mechanical obstruction between gut microbiota and the host. Deterioration of the gut mucosal barrier may expedite biological aging by enabling exposure of gut microbes to the mucosal immunity. Further, the compromised mucosal immunity may lead to inflammation and if immunogenic microbial peptide(s) present in the gut mimics host protein(s), they can induce mild autoimmunity. Therefore, the pathology of metabolic disorders may be related to molecular mimicry stimulated by exposure of gut microbial peptide(s) during aging. This article reviews gut microbes induced inflammaging which can be a potential probiotic target for the treatment of non-communicable diseases.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Probiotics and Prebiotics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37290/ijpp2641-7197.15:34-44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Aging is associated with deterioration of cellular homeostasis and increased risk for several age-related metabolic disorders like obesity, diabetes mellitus, and cardiovascular diseases. Chronic and low-grade inflammation is linked with metabolic syndromes especially during aging (inflammaging). This inflammaging may enhance the risk for late-onset diseases. Gut microbes show a significant role in the regulation and pathogenesis of various metabolic disorders. Gut mucosal lining is a mechanical obstruction between gut microbiota and the host. Deterioration of the gut mucosal barrier may expedite biological aging by enabling exposure of gut microbes to the mucosal immunity. Further, the compromised mucosal immunity may lead to inflammation and if immunogenic microbial peptide(s) present in the gut mimics host protein(s), they can induce mild autoimmunity. Therefore, the pathology of metabolic disorders may be related to molecular mimicry stimulated by exposure of gut microbial peptide(s) during aging. This article reviews gut microbes induced inflammaging which can be a potential probiotic target for the treatment of non-communicable diseases.
期刊介绍:
The International journal of Probiotics & Prebiotics publishes on online only in an open access format. This is a broad based international, interdisciplinary peer reviewed scientific journal for critical evaluation of research on prebiotics, probiotics and synbiotics. The major goal of this journal is to provide unbiased scientific data to students, researchers, healthcare providers, and the decision makers in the nutraceutical industry to help make informed choices about prebiotics, probiotics and synbiotics. To this end, the journal will publish original research articles and two types of review articles. First, we will publish a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, we will publish a critical evaluation of current human experimental data to help deliver products with medically proven use.